Streetbeat News

Stock Prices

WVE

WAVE Life Sciences (NASDAQ:WVE) has received diverse ratings from 5 analysts over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $13.4, reflecting a 14.82% rise from the previous target. Analysts have adjusted their ratings and price targets based on recent developments, with notable actions from Wells Fargo, Truist Securities, Mizuho, RBC Capital, and HC Wainwright & Co. Despite a decline in revenue growth and challenges in financial metrics like ROE and ROA, WAVE Life Sciences continues to innovate in RNA medicines.

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 1:01 pm

OPRX

OptimizeRx (NASDAQ: OPRX) has received diverse analyst ratings over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 12.31% to $14.6. Analysts from firms like Stifel, JMP Securities, and RBC Capital have maintained positive ratings, reflecting optimism about the company's future performance.

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 1:00 pm

AQMS

Aqua Metals has announced a $7 million public offering of 17.5 million shares of common stock and non-redeemable warrants.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 1:00 pm

HYMTF

TM

TSLA

VWAGY

WKSP

Hyundai Motor Group surpassed Volkswagen Group in operating profit for Q1 2024, with Toyota Group maintaining its lead. Hyundai's diverse portfolio and investments in technical capabilities, including a partnership with Worksport Ltd, contributed to its success. Volkswagen faces challenges in the EV market, particularly in China, and has partnered with Xpeng to improve its position.

Portfolio Pulse from Upwallstreet

May 15, 2024 | 12:55 pm

BNR

Trading for BNR was halted and then resumed at 8:55:00 AM ET. The halt was due to pending news, and trading resumed after the news was released.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:55 pm

HMNF

Trading halt status was updated at 8:55:00 AM ET, indicating a resumption of quotations. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:55 pm

DT

Dynatrace shares are trading higher after the company reported better-than-expected Q4 financial results and approved a share buyback program of up to $500 million.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:51 pm

ATXI

Avenue Therapeutics (NASDAQ:ATXI) reported a Q1 EPS of $(15.40), significantly missing the analyst consensus estimate of $(9.00) by 71.11%. This represents an 85.01% improvement over the $(102.75) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:49 pm

VNDA

Vanda Pharmaceuticals announced positive results from its second Phase III study of tradipitant, confirming its efficacy in preventing motion sickness-related vomiting.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:46 pm

ADIL

Adial Pharmaceuticals (NASDAQ:ADIL) reported a Q1 EPS of $(2.19), significantly missing the analyst consensus estimate of $(0.35) by 525.71%. This represents a 20.36% improvement over the $(2.75) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:45 pm